Global Oligonucleotide CDMO Market and Forecast to 2032

GURUGRAM, India - July 17, 2026 - PRLog -- The global oligonucleotide CDMO market was valued at USD 2.1 billion in 2025 and is projected to reach USD 8 billion by 2032, expanding at a CAGR of 21.05% during the forecast period. Oligonucleotide contract development and manufacturing organizations (CDMOs) provide specialized end-to-end services for the development, process optimization, analytical testing, regulatory support, scale-up, and commercial manufacturing of oligonucleotide-based therapeutics. These include antisense oligonucleotides (ASOs), small interfering RNA (siRNA), guide RNA (gRNA), aptamers, and other emerging nucleic acid modalities. As pharmaceutical and biotechnology companies continue to accelerate the development of RNA-based medicines, demand for highly specialized CDMO partners has increased significantly due to the technical complexity, stringent quality requirements, and capital-intensive nature of oligonucleotide manufacturing. These organizations play a critical role in supporting drug developers from early-stage research through commercial production while ensuring compliance with global GMP standards.

Market expansion is being driven by the rapidly growing pipeline of oligonucleotide therapeutics, increasing outsourcing of development and manufacturing activities, and continuous advances in oligonucleotide synthesis and delivery technologies. Pharmaceutical companies are increasingly relying on experienced CDMOs to reduce development timelines, access specialized manufacturing expertise, and expand production capacity without substantial capital investment. Industry innovation is focused on high-throughput synthesis platforms, continuous manufacturing technologies, GalNAc conjugation, lipid nanoparticle (LNP) delivery systems, automated purification technologies, and commercial-scale GMP production facilities. Strategic investments in manufacturing infrastructure, long-term outsourcing agreements, and collaborations between biotechnology innovators and CDMOs are expected to strengthen the market over the coming years. Growing regulatory approvals for RNA therapeutics and increasing commercialization of precision medicines are also expected to support sustained market growth worldwide.

For more details, please visit: https://apeloconsulting.com/product/global-oligonucleotid...

Data Source

Apelo Consulting employs comprehensive primary and secondary research techniques in developing distinctive data sets and research material for business reports. This report is built by using data and information sourced from Proprietary Information Database, Primary and Secondary Research Methodologies, and In house analysis by Apelo Consulting dedicated team of qualified professionals with deep industry experience and expertise.